Cancer has been progressively redefined over the past 20 years. One of the most active pipelines is immunotherapy, with almost 300 molecules in phase one or phase two trials. In this episode we are discussing if existing immunotherapies have lived up to the expectations and what will drive success for the next wave of products in this evolving market.

Hosted by: Jennifer Curtis

Produced by: Matilda Males and Rohan Giblin

Featuring: Malik Kaman, Jon Roffman, Sharon Karlsberg